Tag: Evotec

Evotec launches a new drug discovery initiative with Sanofi

drug discovery
Evotec AG announced that it has established an initiative with Sanofi through the launch of a BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas.

Evotec and Almirall started a drug discovery collaboration

drug development
Evotec AG (Germany) and Almirall S.A. (Spain), a leading skin-health focused global pharmaceutical company, announced that they have entered into a research collaboration.

Evotec and Celgene to collaborate on targeted protein degradation

Evotec AG announced that Evotec and Celgene Corporation have entered into a third long-term strategic drug discovery and development partnership in the field of targeted protein degradation.

Evotec enters a drug discovery partnership with Centogene

Evotec AG announced that CENTOGENE and Evotec entered into a global strategic collaboration agreement for joint drug discovery projects, developing compounds to treat rare genetic diseases.

Evotec sets up alliance with Novo Nordisk to develop novel diabetes therapies

Evotec AG announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity.

Stealth BioTherapeutics develops new drug in collaboration with Evotec

Stealth BioTherapeutics announced that it is advancing a new pipeline candidate into investigational new drug (IND) enabling studies in collaboration with long-term partner Evotec AG.

Evotec partner Haplogen starts drug discovery collaboration with Bayer

Haplogen, a biotechnology company, has entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases.

Evotec receives €3 million payment from Sanofi

stem cells
Evotec AG announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached its second beta cell therapy milestone, resulting in a payment of €3 million to Evotec.

Evotec and Sanofi join forces to fight infectious diseases

microbiology plates
Evotec signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives.

Evotec and Celgene started oncology partnership

Evotec AG announced that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.

Evotec expands its CRISPR service offering with a licence from ERS Genomics

Evotec AG announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing.

Evotec launched its unique drug development solution

Evotec AG has launched its accelerated drug development service INDiGO. With the launch of INDiGO, Evotec’s expertise and capabilities are uniquely combined to deliver better drug candidates faster and more efficiently.

Evotec and Sanofi will create a new innovation platform in France

test tube
Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.